VivoSeq
Infectious Disease

Plasmodium Falciparum Malaria

65

Pipeline Programs↗

1

Active Trials↗

17

Companies Involved↗

Plasmodium falciparum malaria is a moderately active landscape with 65 programs across 17 companies. The most active players are Hope Pharmaceuticals, Barinthus Biotherapeutics, GSK. 12 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

0/100

Mech. Concentration

14/100

Completion Rate

89/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hope Pharmaceuticals

1 program

Phase 1B

Barinthus Biotherapeutics

1 program

Phase 1GSK logo

GSK

4 programs

Phase 1J

Jomaa Pharma GmbH

1 program

Phase 2P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2K

Kunming Pharmaceuticals, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Dihydroartemisinin-Piperaquine

GSK

Artemether-Lumefantrine Combination

London School of Hygiene and Tropical Medicine

Artemether-Lumefantrine (AL)

Novartis

Artesunate-Amodiaquine Combination

Centers for Disease Control and Prevention

P. Falciparum Infected Erythrocytes

University of Oxford

Phase 118

Yellow Fever Vaccine

Sanofi

Aluminum Phosphate

National Institute of Allergy and Infectious Diseases (NIAID)

Sodium Nitrite

Hope Pharmaceuticals

Imatinib

Novartis

TWINRIX™

GSK

Phase 223

Primaquine

Sanofi

Rabies Vaccine

Novartis

Artesunate

Amivas Inc.

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

KAE609

Novartis

Phase 37

Artesunate-Amodiaquine

Sanofi

Atovaquone/proguanil

Pfizer

Pyronaridine-Artesunate

Medicines for Malaria Venture

Mefloquine-Artesunate

Centers for Disease Control and Prevention

Azithromycin/chloroquine

Pfizer

Approved12

Pyrimethamine

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

Mefloquine

United BioPharma

Imiquimod

Bausch Health Americas, Inc.

Methylene Blue

Provepharm SAS

Atovaquone

Glaxo Dba Glaxosmithkline

Analysis

Modality Breakdown

95%

Small molecule

53 of 56 classified programs — the dominant modality here.

5%ALL OTHERSVaccine24%Protein / enzyme12%

Small molecule leads; the ring shows all 56 classified programs, each share of the total. Modality classified for 100% of 72 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed34 · 81%
Terminated4 · 10%
Unknown status3 · 7%
Recruiting1 · 2%

Clinical Trials

Trial Activity

42 trials

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria
Recruiting·Novartis logoNovartis·Phase 2·NCT05750628·327 enrolled
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
Completed·Novartis logoNovartis·Phase 2·NCT04675931·254 enrolled
ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria
Completed·Sanofi logoSanofi·Phase 3·NCT00316329·1,032 enrolled
Phase IIa Proof of Concept Study of M5717-Pyronaridine in Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Completed·Merck & Co. logoMerck & Co.·Phase 2·NCT05689047·38 enrolled
Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy
Completed·IInstitute of Tropical Medicine, Belgium·Phase 2/3·NCT00701961·48 enrolled
Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria
Completed·Medicines for Malaria Venture logoMedicines for Malaria Venture·Phase 2·NCT00331136·60 enrolled
Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America
Completed·Pfizer logoPfizer·Phase 2/3·NCT00084227·244 enrolled
A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania
Completed·UUniversity of Oxford·N/A·NCT04788862·12 enrolled
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria
Completed·HHuLow·Phase 1·NCT02614404·15 enrolled
Efficacy of Artemether-Lumefantrine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Under 12 Years at Four Sentinel Sites in Mozambique
Completed·CCentro de Investigacao em Saude de Manhica·N/A·NCT06970600·352 enrolled
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5
Completed·UUniversity of Oxford·Phase 1·NCT02181088·26 enrolled
Experimental Vaccine for Plasmodium Falciparum Malaria
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00340431
DSM265 Prophylaxis of Plasmodium Falciparum Malaria
Completed·Medicines for Malaria Venture logoMedicines for Malaria Venture·Phase 1·NCT02562872·24 enrolled
Momordica Charantia and Dihydroartemisinin-piperaquined-primaquine for Uncomplicated Plasmodium Falciparum Malaria Patients in Southwest Sumba Regency
Completed·SSyamsudin Abdillah,Ph.D, Pharm D·Phase 2·NCT05829187·36 enrolled
Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
Completed·Novartis logoNovartis·Phase 2·NCT03334747·188 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)